PubRank

Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.

Clinical Trial ID NCT03018236

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03018236

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 1992 29.45
2 A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006 8.57
3 Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014 6.76
4 Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989 6.58
5 Contingency management for treatment of substance use disorders: a meta-analysis. Addiction 2006 6.18
6 Telomere diseases. N Engl J Med 2009 5.68
7 A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis 1992 4.64
8 Missing data in longitudinal studies. Stat Med 1988 4.33
9 Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 2000 4.07
10 Carcinogenicity of alcoholic beverages. Lancet Oncol 2007 3.98
11 Properties of the urn randomization in clinical trials. Control Clin Trials 1988 2.81
12 Selection models for repeated measurements with non-random dropout: an illustration of sensitivity. Stat Med 1998 2.49
13 Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend 2000 2.45
14 Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav 1998 2.09
15 Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007 2.08
16 A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012 2.03
17 Profile of executive deficits in cocaine and heroin polysubstance users: common and differential effects on separate executive components. Psychopharmacology (Berl) 2006 1.92
18 N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatry 2007 1.90
19 The neurobiology of cocaine addiction. Sci Pract Perspect 2005 1.90
20 An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006 1.82
21 Brain-derived neurotrophic factor and cocaine addiction. Brain Res 2009 1.76
22 General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol 1992 1.74
23 Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health 2007 1.52
24 Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend 2010 1.40
25 Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006 1.39
26 Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 2011 1.38
27 N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011 1.35
28 The genetics of addiction-a translational perspective. Transl Psychiatry 2012 1.30
29 N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci 2003 1.26
30 The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013 1.21
31 Shortened telomeres in individuals with abuse in alcohol consumption. Int J Cancer 2011 1.19
32 New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep 2011 1.09
33 N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology 2012 1.07
34 Association of leukocyte telomere length with type 2 diabetes in mainland Chinese populations. J Clin Endocrinol Metab 2012 1.07
35 N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 2010 1.07
36 An Australian twin study of cannabis and other illicit drug use and misuse, and other psychopathology. Twin Res Hum Genet 2012 1.06
37 Ethanol-BDNF interactions: still more questions than answers. Pharmacol Ther 2008 1.06
38 From neurobiology to treatment: progress against addiction. Nat Neurosci 2002 1.05
39 Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction 2014 0.98
40 Key drug use, health and socio-economic characteristics of young crack users in two Brazilian cities. Int J Drug Policy 2013 0.95
41 Psychometric properties of the sixth version of the Addiction Severity Index (ASI-6) in Brazil. Rev Bras Psiquiatr 2012 0.95
42 A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol 2010 0.93
43 Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res 2011 0.92
44 Genetics of dopamine and its contribution to cocaine addiction. Behav Genet 2006 0.92
45 DNA damage in rats after treatment with methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 2007 0.91
46 Alterations of serum brain-derived neurotrophic factor levels in early alcohol withdrawal. Alcohol Alcohol 2008 0.91
47 Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One 2014 0.90
48 Biomarkers in substance use disorders. ACS Chem Neurosci 2015 0.90
49 Trivializing dependence. Br J Addict 1990 0.88
50 Differential patterns of serum brain-derived neurotrophic factor levels in alcoholic patients with and without delirium tremens during acute withdrawal. Alcohol Clin Exp Res 2010 0.88
51 Cocaine dependence: a fast-track for brain ageing? Mol Psychiatry 2012 0.88
52 Getting a Knack for NAC: N-Acetyl-Cysteine. Innov Clin Neurosci 2011 0.88
53 Oxidative stress and BDNF as possible markers for the severity of crack cocaine use in early withdrawal. Psychopharmacology (Berl) 2014 0.87
54 Brain-derived neurotrophic factor serum levels in alcohol-dependent subjects 6 months after alcohol withdrawal. Alcohol Clin Exp Res 2011 0.86
55 Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res 2006 0.86
56 Increased oxidative DNA damage in patients with alcohol dependence and its correlation with alcohol withdrawal severity. Alcohol Clin Exp Res 2010 0.85
57 The correlation between early alcohol withdrawal severity and oxidative stress in patients with alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry 2008 0.84
58 Alcohol, aging, and the stress response. Alcohol Res Health 1999 0.84
59 Further psychometric study of the Beck Anxiety Inventory including factorial analysis and social anxiety disorder screening. Int J Psychiatry Clin Pract 2011 0.82
60 Excitatory amino acids in epilepsy. Restor Neurol Neurosci 1998 0.80
61 Increase in brain-derived neurotrophic factor expression in early crack cocaine withdrawal. Int J Neuropsychopharmacol 2013 0.80
62 Drug addiction is associated with leukocyte telomere length. Sci Rep 2013 0.80
63 Environmental oxidant pollutant effects on biologic systems: a focus on micronutrient antioxidant-oxidant interactions. Am J Respir Crit Care Med 2002 0.79
64 N-acetylcysteine prevents behavioral and biochemical changes induced by alcohol cessation in rats. Alcohol 2015 0.78
65 A population-based Swedish Twin and Sibling Study of cannabis, stimulant and sedative abuse in men. Drug Alcohol Depend 2015 0.77
66 Protective effect of corn peptides against alcoholic liver injury in men with chronic alcohol consumption: a randomized double-blind placebo-controlled study. Lipids Health Dis 2014 0.77
67 Early abstinence of crack-cocaine is effective to attenuate oxidative stress and to improve antioxidant defences. Psychopharmacology (Berl) 2014 0.76
68 Is brain-derived neurotrophic factor a selective biomarker that predicts cocaine relapse outcomes? Biol Psychiatry 2011 0.76
69 Changes in brain-derived neurotrophic factor (BDNF) during abstinence could be associated with relapse in cocaine-dependent patients. Psychiatry Res 2014 0.76
70 Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet 2015 0.76
71 Total antioxidant capacity is significantly lower in cocaine-dependent and methamphetamine-dependent patients relative to normal controls: results from a preliminary study. Hum Psychopharmacol 2014 0.76
Next 100